PR Newswire
IDAHO FALLS, Idaho, Nov. 16, 2026
IDAHO FALLS, Idaho, Nov. 16, 2026 /PRNewswire/ -- Radnostix, Inc. (formerly International Isotopes Inc.) (OTCQB: INIS) ("Radnostix" or the "Company"), a manufacturer of radioisotope-focused technologies for medical, industrial, and research applications, today announced its financial results for the third quarter and nine months ended September 30, 2026 and the filing of its Quarterly Report on Form 10-Q with the U.S. Securities and Exchange Commission.
Third Quarter and Nine Months 2026 Financial and Operational Summary
Shahe Bagerdjian, President and Chief Executive Officer, commented: "The third quarter showed the recovery of our core Theranostics business, with volumes restored in July and revenue up 15% over last year, and we took an important step to support a customer's NDA with our Type II DMF submission for Sodium Iodide I-131 API. Our Cobalt and Calibration & Reference results were held back by contract timing tied to NRC sealed source amendments and by a global cobalt-57 supply interruption, but we have since begun shipping Gd-153 products for the first time since the global outage. The agreement to sell our Fluorine Products/DUF6 assets to Nano Nuclear Energy, which remains subject to NRC approval and other closing conditions, would allow us to focus on our core radioisotope and medical device businesses. We are still focused on developing our medical devices and building stronger OEM relationships with camera companies for our Calibration & Reference products. Our priorities for the fourth quarter and into 2027 are clear: grow core revenues, convert our Cobalt and Calibration & Reference Products backlog, finalize launch of our Medical Devices products, and control costs."
Segment Highlights
2026 Outlook and Focus Areas
Management's priorities for the remainder of 2026 and into 2027 center on:
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||
2026 | 2025 | $ Change | % | 2026 | 2025 | $ Change | % | ||
Sale of Product | $2,571,035 | $3,277,816 | ($706,781) | -22 % | $7,621,744 | $10,172,036 | ($2,550,292) | -25 % | |
Gross Profit | 1,514,215 | 1,940,019 | (425,804) | -22 % | 4,024,398 | 6,113,615 | (2,089,217) | -34 % | |
Total Operating Expense | 2,297,254 | 2,121,433 | 175,821 | 8 % | 6,951,718 | 6,494,886 | 456,832 | 7 % | |
Op. Loss Before Other | (783,039) | (181,414) | (601,625) | 332 % | (2,927,320) | (381,271) | (2,546,049) | 668 % | |
Other Expense | (59,203) | (22,187) | (37,016) | 167 % | (145,005) | (95,809) | (49,196) | 51 % | |
Net Loss | ($842,242) | ($203,601) | ($638,641) | 314 % | ($3,072,325) | ($477,080) | ($2,595,245) | 544 % | |
Basic EPS (Loss) | – | – | (0.01) | – | |||||
Net Loss/Share (Diluted) | – | – | (0.01) | – | |||||
Wtd. Avg. Shares (Basic) | 531,418,649 | 528,088,472 | 529,664,465 | 526,568,064 | |||||
Wtd. Avg. Shares | 531,418,649 | 528,088,472 | 529,664,465 | 526,568,064 | |||||
Three months ended September 30, | Nine months ended September 30, | ||||||||
2026 | 2025 | $ Change | % | 2026 | 2025 | $ Change | % | ||
Net Loss | ($842,242) | ($203,601) | ($638,641) | 314 % | ($3,072,325) | ($477,080) | ($2,595,245) | 544 % | |
Interest expense, net | 72,177 | 66,301 | 5,876 | 9 % | 212,275 | 192,367 | 19,908 | 10 % | |
Provision for income taxes | — | — | — | — | — | — | — | — | |
Depreciation and | 98,774 | 100,718 | (1,944) | -2 % | 316,047 | 299,698 | 16,349 | 5 % | |
EBITDA | (671,291) | (36,582) | (634,709) | 1735 % | (2,544,003) | 14,985 | (2,558,988) | -17077 % | |
Non-cash stock-based | 118,350 | 29,568 | 88,782 | 300 % | 482,053 | 95,364 | 386,689 | 405 % | |
Adjusted EBITDA | ($552,942) | ($7,015) | ($545,927) | 7782 % | ($2,061,950) | $110,349 | ($2,172,299) | -1969 % | |
About Radnostix (formerly International Isotopes Inc.): Radnostix, Inc. (formerly International Isotopes Inc.) (INIS), established in 1995, with its headquarters in Idaho Falls, ID, USA, manufactures a wide range of radioisotope-focused products. Radnostix manufactures and supplies generic sodium iodide I-131 radio-pharmaceutical drug product for hyperthyroidism and thyroid cancer. Radnostix provides contract manufacturing of various drug products as well as radioisotope API supply for 3rd party theranostics clients. Radnostix manufactures and distributes a complete line of calibration and reference standards for nuclear pharmacies and SPECT/PET imaging systems as well as industrial calibration standards under its RadQual brand. Radnostix also manufactures high activity sealed sources for industrial, medical, and defense applications. Radnostix is developing a portfolio of medical devices for use with diagnostic and therapeutic radiopharmaceutical applications, including our brands EasyFill™, RadVent™, and Lara Detection™. For more information, visit www.radnostix.com.
Non-GAAP Financial Measures
This press release contains financial measures that do not comply with U.S. generally accepted accounting principles ("GAAP"), such as EBITDA and Adjusted EBITDA. EBITDA is defined as net income (loss) plus interest expense, net, income taxes, and depreciation and amortization. Adjusted EBITDA is defined as EBITDA further adjusted to exclude non-cash stock-based compensation. These non-GAAP financial measures are supplemental measures to our results of operations as reported under GAAP. Our management uses these measures to better analyze our financial results and business operations. In management's opinion, these non-GAAP measures are useful to investors and other users of our financial statements by providing greater transparency into the ongoing operating performance of the Company. Such measures should not be considered alternatives to net income (loss) or any other performance measures derived in accordance with GAAP. The Company's measurement of EBITDA and Adjusted EBITDA may not be comparable to similar measures of other companies as they are not performance measures calculated in accordance with GAAP. See the tables above for reconciliations of GAAP to non-GAAP measures.
Radnostix, Inc. (formerly International Isotopes Inc.) Safe Harbor Statement:
Certain statements in this press release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding the expected closing, timing and consideration of the DUF6 Sale; the receipt of NRC and other approvals; the value of any Nano Nuclear Energy Inc. common stock to be received; the timing of execution of Cobalt Products contracts and of NRC sealed source device amendments; recovery of Theranostics Products sales; FDA review of the Company's Drug Master File and close-out of recalls and inspection matters; supply of cobalt-57, gadolinium-153 and other radioisotopes and the clearing of backlog; commercialization timelines for Medical Devices products; start-up of the Company's second facility; and the Company's future growth expectations and liquidity. Information contained in such forward-looking statements is based on current expectations and is subject to change. These statements involve a number of risks, uncertainties and other factors that could cause actual results, performance, or achievements of Radnostix, Inc. to be materially different from any future results, performance or achievements of the Company expressed or implied by these forward-looking statements, including the risk that the conditions to closing the DUF6 Sale are not satisfied and the DUF6 Sale does not close. Other factors, which could materially affect such forward-looking statements, can be found in the Company's filings with the Securities and Exchange Commission at www.sec.gov, including the risk factors in its Annual Report on Form 10-K for the year ended December 31, 2025 and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026. Investors, potential investors, and other readers are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements made herein are only made as of the date of this press release and Radnostix, Inc. undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Radnostix Contact:
ir@intisoid.com
radnostix.com
SOURCE International Isotopes Inc.
